Decreased efficacy of a COVID-19 vaccine due to mutations present in early SARS-CoV-2 variants of concern
P. A. Weidenbacher, N. Friedland, M. Sanyal, M. K. Morris, J. Do, C. Hanson, P. S. Kim
This study evaluates the efficacy of a pan-sarbecovirus vaccine candidate against SARS-CoV-2 variants, finding that omitting strain-specific mutations improves cross-reactive neutralizing antibody responses.
bioRxiv · Jun 27, 2023 · PreprintBiochemistry